Efficacy of long‐term adrenocorticotropic hormone therapy for West syndrome: A retrospective multicenter case series

Objectives Long‐term adrenocorticotropic therapy (LT‐ACTH), which consisted of 2‐4 weeks of daily injections of adrenocorticotropic hormone (ACTH) and subsequent months of weekly injections, was tried for relapsed West syndrome (WS) or other intractable epilepsies in small case reports. Our aim was...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Epilepsia Open 2021-06, Vol.6 (2), p.402-412
Hauptverfasser: Baba, Shimpei, Okanishi, Tohru, Homma, Yoichiro, Yoshida, Takeshi, Goto, Tomohide, Fukasawa, Tatsuya, Kobayashi, Satoru, Kamei, Atsushi, Fujii, Yuji, Hino‐Fukuyo, Naomi, Yamada, Keitaro, Daida, Atsuro, Kawawaki, Hisashi, Hoshino, Hideki, Sejima, Hitoshi, Ishida, Yusuke, Okazaki, Tetsuya, Inui, Takehiko, Kanai, Sotaro, Motoi, Hirotaka, Itamura, Shinji, Nishimura, Mitsuyo, Enoki, Hideo, Fujimoto, Ayataka
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 412
container_issue 2
container_start_page 402
container_title Epilepsia Open
container_volume 6
creator Baba, Shimpei
Okanishi, Tohru
Homma, Yoichiro
Yoshida, Takeshi
Goto, Tomohide
Fukasawa, Tatsuya
Kobayashi, Satoru
Kamei, Atsushi
Fujii, Yuji
Hino‐Fukuyo, Naomi
Yamada, Keitaro
Daida, Atsuro
Kawawaki, Hisashi
Hoshino, Hideki
Sejima, Hitoshi
Ishida, Yusuke
Okazaki, Tetsuya
Inui, Takehiko
Kanai, Sotaro
Motoi, Hirotaka
Itamura, Shinji
Nishimura, Mitsuyo
Enoki, Hideo
Fujimoto, Ayataka
description Objectives Long‐term adrenocorticotropic therapy (LT‐ACTH), which consisted of 2‐4 weeks of daily injections of adrenocorticotropic hormone (ACTH) and subsequent months of weekly injections, was tried for relapsed West syndrome (WS) or other intractable epilepsies in small case reports. Our aim was to explore the efficacy of LT‐ACTH for preventing WS relapse, as well as the prevalence of its adverse events. Methods This is a retrospective, nationwide, multicenter case series of patients with WS who underwent LT‐ACTH. Clinical information of the patients and protocol of LT‐ACTH were collected from participating institutes in this study. We defined clinical response to ACTH as achievement of hypsarrhythmia and epileptic spasms resolution. Patients who responded to daily ACTH injections were identified and assessed whether they experienced WS relapse during/after the weekly ACTH injection period. The outcome was measured by the nonrelapse rate at 24 months after daily ACTH injections using the Kaplan‐Meier method. Results Clinical information of 16 children with WS was analyzed. The median age at LT‐ACTH initiation was 14.5 months (range: 7‐68 months). Thirteen (81%) patients had previously undergone conventional ACTH treatment. The LT‐ACTH regimens comprised a median of 16 days of daily injections (range: 11‐28 days) and 10 months of weekly injections (range: 3‐22 months). Seven patients experienced WS relapse during/after subsequent weekly ACTH period, and the nonrelapse rate at 24 months after daily injections was estimated at 60.6% (95% confidence interval: 32.3%‐80.0%). Height stagnation, hypertension, and irritability were observed; lethal adverse events were not reported. Significance Our study firstly explored the efficacy of LT‐ACTH for preventing WS relapse. LT‐ACTH might be a treatment option for patients with relapsed or intractable WS; however, we note that our study is limited by its small sample size and the lack of an appropriate control group.
doi_str_mv 10.1002/epi4.12497
format Article
fullrecord <record><control><sourceid>gale_webof</sourceid><recordid>TN_cdi_webofscience_primary_000657725200001</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A710998850</galeid><doaj_id>oai_doaj_org_article_56142fc7aa2543ce9e1f76d9d0a1ecd0</doaj_id><sourcerecordid>A710998850</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6477-3c5b65beeac4122f1eb653f415e95631327886dc603b42e72fe8984ecca914ab3</originalsourceid><addsrcrecordid>eNqNks2O0zAUhSMEYkbDbHgAZIkdqMV2_BOzQKqqApVGggWIpeU4161HjR2ctKg7HoFn5ElwJqWa2SBWSZzvHp1zfYriOcFzgjF9A51nc0KZko-KS8oknilaqsf33i-K676_xRgTRQkR-GlxUTKsuKjEZXFYOeetsUcUHdrFsPn989cAqUWmSRCijWnwNg4pdt6ibUxtDICGLSTTHZGLCX2DfkD9MTQptvAWLVCCTPcd2MEfALX7XRaAkDWRNT2gHpKH_lnxxJldD9en51Xx9f3qy_Lj7ObTh_VycTOzgkk5Ky2vBa8BjGWEUkcgf5aOEQ7Zf0lKKqtKNFbgsmYUJHVQqYqBtUYRZuryqlhPuk00t7pLvjXpqKPx-u4gpo02Y8IdaC4Io85KYyhnpQUFxEnRqAYbArbBWevdpNXt6xaaMVQyuweiD_8Ev9WbeNAVEUIqkQVengRS_L7Pe9O3cZ9Czq8pL5lUinKeqflEbUx25YPL2zf5hkwDbb6KAM7n84UkWKmq4qOvV9OAzXvvE7izJYL12BE9dkTfdSTDL-6HOKN_G5GBagJ-QB1dbz0EC2cst0hwKSmneCzU0g9m8DEs4z4MefT1_49mmpzonOf4D8969XnNJvd_AORh6o8</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2534799255</pqid></control><display><type>article</type><title>Efficacy of long‐term adrenocorticotropic hormone therapy for West syndrome: A retrospective multicenter case series</title><source>Access via Wiley Online Library</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Web of Science - Science Citation Index Expanded - 2021&lt;img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /&gt;</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><creator>Baba, Shimpei ; Okanishi, Tohru ; Homma, Yoichiro ; Yoshida, Takeshi ; Goto, Tomohide ; Fukasawa, Tatsuya ; Kobayashi, Satoru ; Kamei, Atsushi ; Fujii, Yuji ; Hino‐Fukuyo, Naomi ; Yamada, Keitaro ; Daida, Atsuro ; Kawawaki, Hisashi ; Hoshino, Hideki ; Sejima, Hitoshi ; Ishida, Yusuke ; Okazaki, Tetsuya ; Inui, Takehiko ; Kanai, Sotaro ; Motoi, Hirotaka ; Itamura, Shinji ; Nishimura, Mitsuyo ; Enoki, Hideo ; Fujimoto, Ayataka</creator><creatorcontrib>Baba, Shimpei ; Okanishi, Tohru ; Homma, Yoichiro ; Yoshida, Takeshi ; Goto, Tomohide ; Fukasawa, Tatsuya ; Kobayashi, Satoru ; Kamei, Atsushi ; Fujii, Yuji ; Hino‐Fukuyo, Naomi ; Yamada, Keitaro ; Daida, Atsuro ; Kawawaki, Hisashi ; Hoshino, Hideki ; Sejima, Hitoshi ; Ishida, Yusuke ; Okazaki, Tetsuya ; Inui, Takehiko ; Kanai, Sotaro ; Motoi, Hirotaka ; Itamura, Shinji ; Nishimura, Mitsuyo ; Enoki, Hideo ; Fujimoto, Ayataka</creatorcontrib><description>Objectives Long‐term adrenocorticotropic therapy (LT‐ACTH), which consisted of 2‐4 weeks of daily injections of adrenocorticotropic hormone (ACTH) and subsequent months of weekly injections, was tried for relapsed West syndrome (WS) or other intractable epilepsies in small case reports. Our aim was to explore the efficacy of LT‐ACTH for preventing WS relapse, as well as the prevalence of its adverse events. Methods This is a retrospective, nationwide, multicenter case series of patients with WS who underwent LT‐ACTH. Clinical information of the patients and protocol of LT‐ACTH were collected from participating institutes in this study. We defined clinical response to ACTH as achievement of hypsarrhythmia and epileptic spasms resolution. Patients who responded to daily ACTH injections were identified and assessed whether they experienced WS relapse during/after the weekly ACTH injection period. The outcome was measured by the nonrelapse rate at 24 months after daily ACTH injections using the Kaplan‐Meier method. Results Clinical information of 16 children with WS was analyzed. The median age at LT‐ACTH initiation was 14.5 months (range: 7‐68 months). Thirteen (81%) patients had previously undergone conventional ACTH treatment. The LT‐ACTH regimens comprised a median of 16 days of daily injections (range: 11‐28 days) and 10 months of weekly injections (range: 3‐22 months). Seven patients experienced WS relapse during/after subsequent weekly ACTH period, and the nonrelapse rate at 24 months after daily injections was estimated at 60.6% (95% confidence interval: 32.3%‐80.0%). Height stagnation, hypertension, and irritability were observed; lethal adverse events were not reported. Significance Our study firstly explored the efficacy of LT‐ACTH for preventing WS relapse. LT‐ACTH might be a treatment option for patients with relapsed or intractable WS; however, we note that our study is limited by its small sample size and the lack of an appropriate control group.</description><identifier>ISSN: 2470-9239</identifier><identifier>EISSN: 2470-9239</identifier><identifier>DOI: 10.1002/epi4.12497</identifier><identifier>PMID: 34095686</identifier><language>eng</language><publisher>HOBOKEN: Wiley</publisher><subject>ACTH ; adrenocorticotropic hormone ; Adrenocorticotropic Hormone - adverse effects ; Adrenocorticotropic Hormone - therapeutic use ; Analysis ; Care and treatment ; Child ; Clinical Neurology ; Convulsions &amp; seizures ; Drug dosages ; Electroencephalography ; Endocrine therapy ; Epilepsy ; Full‐length Original Research ; Humans ; Hypertension ; Life Sciences &amp; Biomedicine ; long‐term treatment ; Metabolism ; Nationwide survey ; Neurosciences ; Neurosciences &amp; Neurology ; Patients ; Pediatrics ; Questionnaires ; Recurrence ; retrospective case series ; Retrospective Studies ; Science &amp; Technology ; Spasms, Infantile - drug therapy ; West syndrome</subject><ispartof>Epilepsia Open, 2021-06, Vol.6 (2), p.402-412</ispartof><rights>2021 The Authors. published by Wiley Periodicals LLC on behalf of International League Against Epilepsy</rights><rights>2021 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.</rights><rights>COPYRIGHT 2021 John Wiley &amp; Sons, Inc.</rights><rights>2021. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>7</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000657725200001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c6477-3c5b65beeac4122f1eb653f415e95631327886dc603b42e72fe8984ecca914ab3</citedby><cites>FETCH-LOGICAL-c6477-3c5b65beeac4122f1eb653f415e95631327886dc603b42e72fe8984ecca914ab3</cites><orcidid>0000-0002-0596-3338 ; 0000-0002-3017-9078 ; 0000-0003-0992-064X ; 0000-0002-7320-2346 ; 0000-0002-5308-2965 ; 0000-0003-3842-9294 ; 0000-0003-3295-2236 ; 0000-0003-1350-7700</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166796/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166796/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,866,887,1419,2106,2118,11571,27933,27934,39267,45583,45584,46061,46485,53800,53802</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34095686$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Baba, Shimpei</creatorcontrib><creatorcontrib>Okanishi, Tohru</creatorcontrib><creatorcontrib>Homma, Yoichiro</creatorcontrib><creatorcontrib>Yoshida, Takeshi</creatorcontrib><creatorcontrib>Goto, Tomohide</creatorcontrib><creatorcontrib>Fukasawa, Tatsuya</creatorcontrib><creatorcontrib>Kobayashi, Satoru</creatorcontrib><creatorcontrib>Kamei, Atsushi</creatorcontrib><creatorcontrib>Fujii, Yuji</creatorcontrib><creatorcontrib>Hino‐Fukuyo, Naomi</creatorcontrib><creatorcontrib>Yamada, Keitaro</creatorcontrib><creatorcontrib>Daida, Atsuro</creatorcontrib><creatorcontrib>Kawawaki, Hisashi</creatorcontrib><creatorcontrib>Hoshino, Hideki</creatorcontrib><creatorcontrib>Sejima, Hitoshi</creatorcontrib><creatorcontrib>Ishida, Yusuke</creatorcontrib><creatorcontrib>Okazaki, Tetsuya</creatorcontrib><creatorcontrib>Inui, Takehiko</creatorcontrib><creatorcontrib>Kanai, Sotaro</creatorcontrib><creatorcontrib>Motoi, Hirotaka</creatorcontrib><creatorcontrib>Itamura, Shinji</creatorcontrib><creatorcontrib>Nishimura, Mitsuyo</creatorcontrib><creatorcontrib>Enoki, Hideo</creatorcontrib><creatorcontrib>Fujimoto, Ayataka</creatorcontrib><title>Efficacy of long‐term adrenocorticotropic hormone therapy for West syndrome: A retrospective multicenter case series</title><title>Epilepsia Open</title><addtitle>EPILEPSIA OPEN</addtitle><addtitle>Epilepsia Open</addtitle><description>Objectives Long‐term adrenocorticotropic therapy (LT‐ACTH), which consisted of 2‐4 weeks of daily injections of adrenocorticotropic hormone (ACTH) and subsequent months of weekly injections, was tried for relapsed West syndrome (WS) or other intractable epilepsies in small case reports. Our aim was to explore the efficacy of LT‐ACTH for preventing WS relapse, as well as the prevalence of its adverse events. Methods This is a retrospective, nationwide, multicenter case series of patients with WS who underwent LT‐ACTH. Clinical information of the patients and protocol of LT‐ACTH were collected from participating institutes in this study. We defined clinical response to ACTH as achievement of hypsarrhythmia and epileptic spasms resolution. Patients who responded to daily ACTH injections were identified and assessed whether they experienced WS relapse during/after the weekly ACTH injection period. The outcome was measured by the nonrelapse rate at 24 months after daily ACTH injections using the Kaplan‐Meier method. Results Clinical information of 16 children with WS was analyzed. The median age at LT‐ACTH initiation was 14.5 months (range: 7‐68 months). Thirteen (81%) patients had previously undergone conventional ACTH treatment. The LT‐ACTH regimens comprised a median of 16 days of daily injections (range: 11‐28 days) and 10 months of weekly injections (range: 3‐22 months). Seven patients experienced WS relapse during/after subsequent weekly ACTH period, and the nonrelapse rate at 24 months after daily injections was estimated at 60.6% (95% confidence interval: 32.3%‐80.0%). Height stagnation, hypertension, and irritability were observed; lethal adverse events were not reported. Significance Our study firstly explored the efficacy of LT‐ACTH for preventing WS relapse. LT‐ACTH might be a treatment option for patients with relapsed or intractable WS; however, we note that our study is limited by its small sample size and the lack of an appropriate control group.</description><subject>ACTH</subject><subject>adrenocorticotropic hormone</subject><subject>Adrenocorticotropic Hormone - adverse effects</subject><subject>Adrenocorticotropic Hormone - therapeutic use</subject><subject>Analysis</subject><subject>Care and treatment</subject><subject>Child</subject><subject>Clinical Neurology</subject><subject>Convulsions &amp; seizures</subject><subject>Drug dosages</subject><subject>Electroencephalography</subject><subject>Endocrine therapy</subject><subject>Epilepsy</subject><subject>Full‐length Original Research</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Life Sciences &amp; Biomedicine</subject><subject>long‐term treatment</subject><subject>Metabolism</subject><subject>Nationwide survey</subject><subject>Neurosciences</subject><subject>Neurosciences &amp; Neurology</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Questionnaires</subject><subject>Recurrence</subject><subject>retrospective case series</subject><subject>Retrospective Studies</subject><subject>Science &amp; Technology</subject><subject>Spasms, Infantile - drug therapy</subject><subject>West syndrome</subject><issn>2470-9239</issn><issn>2470-9239</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>HGBXW</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>DOA</sourceid><recordid>eNqNks2O0zAUhSMEYkbDbHgAZIkdqMV2_BOzQKqqApVGggWIpeU4161HjR2ctKg7HoFn5ElwJqWa2SBWSZzvHp1zfYriOcFzgjF9A51nc0KZko-KS8oknilaqsf33i-K676_xRgTRQkR-GlxUTKsuKjEZXFYOeetsUcUHdrFsPn989cAqUWmSRCijWnwNg4pdt6ibUxtDICGLSTTHZGLCX2DfkD9MTQptvAWLVCCTPcd2MEfALX7XRaAkDWRNT2gHpKH_lnxxJldD9en51Xx9f3qy_Lj7ObTh_VycTOzgkk5Ky2vBa8BjGWEUkcgf5aOEQ7Zf0lKKqtKNFbgsmYUJHVQqYqBtUYRZuryqlhPuk00t7pLvjXpqKPx-u4gpo02Y8IdaC4Io85KYyhnpQUFxEnRqAYbArbBWevdpNXt6xaaMVQyuweiD_8Ev9WbeNAVEUIqkQVengRS_L7Pe9O3cZ9Czq8pL5lUinKeqflEbUx25YPL2zf5hkwDbb6KAM7n84UkWKmq4qOvV9OAzXvvE7izJYL12BE9dkTfdSTDL-6HOKN_G5GBagJ-QB1dbz0EC2cst0hwKSmneCzU0g9m8DEs4z4MefT1_49mmpzonOf4D8969XnNJvd_AORh6o8</recordid><startdate>202106</startdate><enddate>202106</enddate><creator>Baba, Shimpei</creator><creator>Okanishi, Tohru</creator><creator>Homma, Yoichiro</creator><creator>Yoshida, Takeshi</creator><creator>Goto, Tomohide</creator><creator>Fukasawa, Tatsuya</creator><creator>Kobayashi, Satoru</creator><creator>Kamei, Atsushi</creator><creator>Fujii, Yuji</creator><creator>Hino‐Fukuyo, Naomi</creator><creator>Yamada, Keitaro</creator><creator>Daida, Atsuro</creator><creator>Kawawaki, Hisashi</creator><creator>Hoshino, Hideki</creator><creator>Sejima, Hitoshi</creator><creator>Ishida, Yusuke</creator><creator>Okazaki, Tetsuya</creator><creator>Inui, Takehiko</creator><creator>Kanai, Sotaro</creator><creator>Motoi, Hirotaka</creator><creator>Itamura, Shinji</creator><creator>Nishimura, Mitsuyo</creator><creator>Enoki, Hideo</creator><creator>Fujimoto, Ayataka</creator><general>Wiley</general><general>John Wiley &amp; Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-0596-3338</orcidid><orcidid>https://orcid.org/0000-0002-3017-9078</orcidid><orcidid>https://orcid.org/0000-0003-0992-064X</orcidid><orcidid>https://orcid.org/0000-0002-7320-2346</orcidid><orcidid>https://orcid.org/0000-0002-5308-2965</orcidid><orcidid>https://orcid.org/0000-0003-3842-9294</orcidid><orcidid>https://orcid.org/0000-0003-3295-2236</orcidid><orcidid>https://orcid.org/0000-0003-1350-7700</orcidid></search><sort><creationdate>202106</creationdate><title>Efficacy of long‐term adrenocorticotropic hormone therapy for West syndrome: A retrospective multicenter case series</title><author>Baba, Shimpei ; Okanishi, Tohru ; Homma, Yoichiro ; Yoshida, Takeshi ; Goto, Tomohide ; Fukasawa, Tatsuya ; Kobayashi, Satoru ; Kamei, Atsushi ; Fujii, Yuji ; Hino‐Fukuyo, Naomi ; Yamada, Keitaro ; Daida, Atsuro ; Kawawaki, Hisashi ; Hoshino, Hideki ; Sejima, Hitoshi ; Ishida, Yusuke ; Okazaki, Tetsuya ; Inui, Takehiko ; Kanai, Sotaro ; Motoi, Hirotaka ; Itamura, Shinji ; Nishimura, Mitsuyo ; Enoki, Hideo ; Fujimoto, Ayataka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6477-3c5b65beeac4122f1eb653f415e95631327886dc603b42e72fe8984ecca914ab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>ACTH</topic><topic>adrenocorticotropic hormone</topic><topic>Adrenocorticotropic Hormone - adverse effects</topic><topic>Adrenocorticotropic Hormone - therapeutic use</topic><topic>Analysis</topic><topic>Care and treatment</topic><topic>Child</topic><topic>Clinical Neurology</topic><topic>Convulsions &amp; seizures</topic><topic>Drug dosages</topic><topic>Electroencephalography</topic><topic>Endocrine therapy</topic><topic>Epilepsy</topic><topic>Full‐length Original Research</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Life Sciences &amp; Biomedicine</topic><topic>long‐term treatment</topic><topic>Metabolism</topic><topic>Nationwide survey</topic><topic>Neurosciences</topic><topic>Neurosciences &amp; Neurology</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Questionnaires</topic><topic>Recurrence</topic><topic>retrospective case series</topic><topic>Retrospective Studies</topic><topic>Science &amp; Technology</topic><topic>Spasms, Infantile - drug therapy</topic><topic>West syndrome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baba, Shimpei</creatorcontrib><creatorcontrib>Okanishi, Tohru</creatorcontrib><creatorcontrib>Homma, Yoichiro</creatorcontrib><creatorcontrib>Yoshida, Takeshi</creatorcontrib><creatorcontrib>Goto, Tomohide</creatorcontrib><creatorcontrib>Fukasawa, Tatsuya</creatorcontrib><creatorcontrib>Kobayashi, Satoru</creatorcontrib><creatorcontrib>Kamei, Atsushi</creatorcontrib><creatorcontrib>Fujii, Yuji</creatorcontrib><creatorcontrib>Hino‐Fukuyo, Naomi</creatorcontrib><creatorcontrib>Yamada, Keitaro</creatorcontrib><creatorcontrib>Daida, Atsuro</creatorcontrib><creatorcontrib>Kawawaki, Hisashi</creatorcontrib><creatorcontrib>Hoshino, Hideki</creatorcontrib><creatorcontrib>Sejima, Hitoshi</creatorcontrib><creatorcontrib>Ishida, Yusuke</creatorcontrib><creatorcontrib>Okazaki, Tetsuya</creatorcontrib><creatorcontrib>Inui, Takehiko</creatorcontrib><creatorcontrib>Kanai, Sotaro</creatorcontrib><creatorcontrib>Motoi, Hirotaka</creatorcontrib><creatorcontrib>Itamura, Shinji</creatorcontrib><creatorcontrib>Nishimura, Mitsuyo</creatorcontrib><creatorcontrib>Enoki, Hideo</creatorcontrib><creatorcontrib>Fujimoto, Ayataka</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Epilepsia Open</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baba, Shimpei</au><au>Okanishi, Tohru</au><au>Homma, Yoichiro</au><au>Yoshida, Takeshi</au><au>Goto, Tomohide</au><au>Fukasawa, Tatsuya</au><au>Kobayashi, Satoru</au><au>Kamei, Atsushi</au><au>Fujii, Yuji</au><au>Hino‐Fukuyo, Naomi</au><au>Yamada, Keitaro</au><au>Daida, Atsuro</au><au>Kawawaki, Hisashi</au><au>Hoshino, Hideki</au><au>Sejima, Hitoshi</au><au>Ishida, Yusuke</au><au>Okazaki, Tetsuya</au><au>Inui, Takehiko</au><au>Kanai, Sotaro</au><au>Motoi, Hirotaka</au><au>Itamura, Shinji</au><au>Nishimura, Mitsuyo</au><au>Enoki, Hideo</au><au>Fujimoto, Ayataka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of long‐term adrenocorticotropic hormone therapy for West syndrome: A retrospective multicenter case series</atitle><jtitle>Epilepsia Open</jtitle><stitle>EPILEPSIA OPEN</stitle><addtitle>Epilepsia Open</addtitle><date>2021-06</date><risdate>2021</risdate><volume>6</volume><issue>2</issue><spage>402</spage><epage>412</epage><pages>402-412</pages><issn>2470-9239</issn><eissn>2470-9239</eissn><abstract>Objectives Long‐term adrenocorticotropic therapy (LT‐ACTH), which consisted of 2‐4 weeks of daily injections of adrenocorticotropic hormone (ACTH) and subsequent months of weekly injections, was tried for relapsed West syndrome (WS) or other intractable epilepsies in small case reports. Our aim was to explore the efficacy of LT‐ACTH for preventing WS relapse, as well as the prevalence of its adverse events. Methods This is a retrospective, nationwide, multicenter case series of patients with WS who underwent LT‐ACTH. Clinical information of the patients and protocol of LT‐ACTH were collected from participating institutes in this study. We defined clinical response to ACTH as achievement of hypsarrhythmia and epileptic spasms resolution. Patients who responded to daily ACTH injections were identified and assessed whether they experienced WS relapse during/after the weekly ACTH injection period. The outcome was measured by the nonrelapse rate at 24 months after daily ACTH injections using the Kaplan‐Meier method. Results Clinical information of 16 children with WS was analyzed. The median age at LT‐ACTH initiation was 14.5 months (range: 7‐68 months). Thirteen (81%) patients had previously undergone conventional ACTH treatment. The LT‐ACTH regimens comprised a median of 16 days of daily injections (range: 11‐28 days) and 10 months of weekly injections (range: 3‐22 months). Seven patients experienced WS relapse during/after subsequent weekly ACTH period, and the nonrelapse rate at 24 months after daily injections was estimated at 60.6% (95% confidence interval: 32.3%‐80.0%). Height stagnation, hypertension, and irritability were observed; lethal adverse events were not reported. Significance Our study firstly explored the efficacy of LT‐ACTH for preventing WS relapse. LT‐ACTH might be a treatment option for patients with relapsed or intractable WS; however, we note that our study is limited by its small sample size and the lack of an appropriate control group.</abstract><cop>HOBOKEN</cop><pub>Wiley</pub><pmid>34095686</pmid><doi>10.1002/epi4.12497</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-0596-3338</orcidid><orcidid>https://orcid.org/0000-0002-3017-9078</orcidid><orcidid>https://orcid.org/0000-0003-0992-064X</orcidid><orcidid>https://orcid.org/0000-0002-7320-2346</orcidid><orcidid>https://orcid.org/0000-0002-5308-2965</orcidid><orcidid>https://orcid.org/0000-0003-3842-9294</orcidid><orcidid>https://orcid.org/0000-0003-3295-2236</orcidid><orcidid>https://orcid.org/0000-0003-1350-7700</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2470-9239
ispartof Epilepsia Open, 2021-06, Vol.6 (2), p.402-412
issn 2470-9239
2470-9239
language eng
recordid cdi_webofscience_primary_000657725200001
source Access via Wiley Online Library; MEDLINE; DOAJ Directory of Open Access Journals; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Online Library (Open Access Collection); PubMed Central
subjects ACTH
adrenocorticotropic hormone
Adrenocorticotropic Hormone - adverse effects
Adrenocorticotropic Hormone - therapeutic use
Analysis
Care and treatment
Child
Clinical Neurology
Convulsions & seizures
Drug dosages
Electroencephalography
Endocrine therapy
Epilepsy
Full‐length Original Research
Humans
Hypertension
Life Sciences & Biomedicine
long‐term treatment
Metabolism
Nationwide survey
Neurosciences
Neurosciences & Neurology
Patients
Pediatrics
Questionnaires
Recurrence
retrospective case series
Retrospective Studies
Science & Technology
Spasms, Infantile - drug therapy
West syndrome
title Efficacy of long‐term adrenocorticotropic hormone therapy for West syndrome: A retrospective multicenter case series
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-01T13%3A39%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20long%E2%80%90term%20adrenocorticotropic%20hormone%20therapy%20for%20West%20syndrome:%20A%20retrospective%20multicenter%20case%20series&rft.jtitle=Epilepsia%20Open&rft.au=Baba,%20Shimpei&rft.date=2021-06&rft.volume=6&rft.issue=2&rft.spage=402&rft.epage=412&rft.pages=402-412&rft.issn=2470-9239&rft.eissn=2470-9239&rft_id=info:doi/10.1002/epi4.12497&rft_dat=%3Cgale_webof%3EA710998850%3C/gale_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2534799255&rft_id=info:pmid/34095686&rft_galeid=A710998850&rft_doaj_id=oai_doaj_org_article_56142fc7aa2543ce9e1f76d9d0a1ecd0&rfr_iscdi=true